The Top 5 Biosimilars Articles for the Year of 2018

The Center for Biosimilars® recaps the top news of 2018.


Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the most-read biosimilars articles for the year of 2018.

Number 5: In July, the FDA released its Biosimilar Action Plan.

Number 4: In September, the State of California sued AbbVie for allegedly using kickbacks and nurse ambassadors to boost adalimumab sales.

Number 3: In June, the FDA approved the first pegfilgrastim biosimilar, Fulphila.

Number 2: In April, the United Kingdom’s National Health Service prepared for the arrival of biosimilar adalimumab.

Number 1: In June, the FDA rejected Amgen’s trastuzumab biosimilar, ABP 980.

To read all of these articles and more, visit